Age- and Sex-Specific Incidence of Cerebral Venous Sinus Thrombosis Associated With Ad26.COV2.S COVID-19 Vaccination JAMA

Post author By EvidenceNotFear
Post date 1 November 2021

In this population-based cohort study, we found that the CVST incidence rate 15 days after Ad26.COV2.S vaccination was significantly higher than the prepandemic rate. However, the higher rate of this rare adverse effect must be considered in the context of the effectiveness of the vaccine in preventing COVID-19 (absolute reduction of severe or critical COVID-19 of 940 per 100 000 PY).

http://archive.today/2021.11.02-171706/https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2785610

Tags Blood Clots, COVID-19, CVST, JAMA, Janssen, Johnson & Johnson, Mayo Clinic, Newsweek, Side-effects, USA, Vaccination, Vaccine Damage

Info This site is a curated archive of articles with a link to the source. Keywords and topics covered in the publication can be found above. Click on the tag to view a listing of similar articles.
Links Are any links broken? The page may have been taken down. Visit archive.is or archive.org to view the archive snapshot.
Links Help fight censorship and preserve information on the internet. Archive this source and links on archive.is and archive.org. Save a local copy on your own hard drive.